Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bamlanivimab Alone and with Etesevimab for COVID-19 Prevention in Nursing Homes
NCT04497987Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2020
- Primary completion
- Jan 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bamlanivimab and etesevimab in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percentage of Participants With COVID-19 at Week 8. Started Aug 2020; status: completed.
02
Drugs
bamlanivimabetesevimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04497987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04497987.